Exenatide extended-release: A once-weekly option for patients with type 2 diabetes

被引：3

作者：

Anderson, Zachary L. ^{[1
]}

Clements, Jennifer N. ^{[1
]}

机构：

[1] Presbyterian Coll, Sch Pharm, Clinton, SC 29325 USA

来源：

JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2014年 / 27卷 / 06期

关键词：

exenatide; extended-release; glucagon-like peptide-1; type; 2; diabetes; management; pharmacotherapy; OPEN-LABEL; PIOGLITAZONE; SITAGLIPTIN; EFFICACY; SAFETY;

D O I：

10.1097/01.JAA.0000443811.42907.a5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Exenatide extended-release is a new long-acting glucagon-like peptide-1 agonist that may be an attractive option for patients desiring to lose weight, who are prone to hypoglycemic episodes, and who have not achieved desired glycemic control with current therapy.

引用

页码：44 / 46

页数：3

共 9 条

[1]

[Anonymous], 2012, BYD PACK INS

[2] Clinical Implications of Exenatide as a Twice-Daily or Once-Weekly Therapy for Type 2 Diabetes [J].

Aroda, Vanita R. ;

DeYoung, Mary Beth .

POSTGRADUATE MEDICINE, 2011, 123 (05) :228-238

[3] DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes [J].

Blevins, Thomas ;

Pullman, John ;

Malloy, Jaret ;

Yan, Ping ;

Taylor, Kristin ;

Schulteis, Christine ;

Trautmann, Michael ;

Porter, Lisa .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (05) :1301-1310

[4] Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study [J].

Buse, John B. ;

Nauck, Michael ;

Forst, Thomas ;

Sheu, Wayne H-H ;

Shenouda, Sylvia K. ;

Heilmann, Cory R. ;

Hoogwerf, Byron J. ;

Gao, Aijun ;

Boardman, Marilyn K. ;

Fineman, Mark ;

Porter, Lisa ;

Schernthaner, Guntram .

LANCET, 2013, 381 (9861) :117-124

[5] DURATION-1 Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks [J].

Buse, John B. ;

Drucker, Daniel J. ;

Taylor, Kristin L. ;

Kim, Terri ;

Walsh, Brandon ;

Hu, Hao ;

Wilhelm, Ken ;

Trautmann, Michael ;

Shen, Larry Z. ;

Porter, Lisa E. .

DIABETES CARE, 2010, 33 (06) :1255-1261

[6] Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial [J].

Diamant, Michaela ;

Van Gaal, Luc ;

Stranks, Stephen ;

Northrup, Justin ;

Cao, Dachuang ;

Taylor, Kristin ;

Trautmann, Michael .

LANCET, 2010, 375 (9733) :2234-2243

[7]

Lorenzi G., 2010, CLIN DIABETES, V28, P157

[8] Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) A 26-week double-blind study [J].

Russell-Jones, David ;

Cuddihy, Robert M. ;

Hanefeld, Markolf ;

Kumar, Ajay ;

Gonzalez, Jose G. ;

Chan, Melanie ;

Wolka, Anne M. ;

Boardman, Marilyn K. .

DIABETES CARE, 2012, 35 (02) :252-258

[9] DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide [J].

Wysham, C. ;

Bergenstal, R. ;

Malloy, J. ;

Yan, P. ;

Walsh, B. ;

Malone, J. ;

Taylor, K. .

DIABETIC MEDICINE, 2011, 28 (06) :705-714

← 1 →